Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

YY-20394, an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, was investigated in a first-in-human study of patients with relapsed or refractory B-cell malignancies. During dose escalation, 25 patients received 20–200 mg of YY-20394 daily. The primary outcome measures were tolerability an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Bo, Qi, Junyuan, Song, Yuqin, Li, Zengjun, Tu, Meifeng, Ping, Lingyan, Liu, Zongliang, Bao, Hanying, Xu, Zusheng, Qiu, Lugui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381505/
https://www.ncbi.nlm.nih.gov/pubmed/34425850
http://dx.doi.org/10.1186/s13045-021-01140-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381505/
https://www.ncbi.nlm.nih.gov/pubmed/34425850
http://dx.doi.org/10.1186/s13045-021-01140-z

Ejemplares similares